359 research outputs found
Immunotherapy before solid organ transplantation: an international transplant community-focused survey
Liver resection and transplantation for intrahepatic cholangiocarcinoma
The incidence of intrahepatic cholangiocarcinoma (iCCA) is increasing worldwide. Although several advances have been made in the past decades to better understand this complex malignancy and to develop new treatment strategies, the prognosis of iCCA remains dismal. Liver resection (LR) is the mainstay of treatment but only a minority of patients are amenable to surgery. In most cases, patients with iCCA will require a major hepatectomy for complete resection of the tumour. This may be contraindicated or increase the surgical burden in patients with chronic liver disease and small remnant liver volume. Lymphadenectomy with a minimal harvest of 6 lymph nodes is considered adequate, as microscopic nodal metastases have been shown in more than 40% of patients. Current 5-year overall survival following LR is in the range of 25%\u201340%. For locally advanced disease not amenable to upfront LR, neoadjuvant locoregional therapies may be used with the aim of converting these patients to resectability or even to transplantation in well-selected cases. Recent studies have shown that liver transplantation (LT) might be a treatment option for patients with unresectable very-early iCCA (i.e. 642 cm), with survival outcomes comparable to those of hepatocellular carcinoma. In patients with unresectable, advanced tumours, confined to the liver who achieve sustained response to neoadjuvant treatment, LT may be considered an option within prospective protocols. The role of adjuvant therapies in iCCA is still under debate. Herein, we review the recent advances in the surgical treatment of iCCA and examine its correlation with locoregional therapies, adjuvant and neo-adjuvant strategies
Optimizing Circulating Tumour DNA Use in the Perioperative Setting for Intrahepatic Cholangiocarcinoma: Diagnosis, Screening, Minimal Residual Disease Detection and Treatment Response Monitoring
In this review, we present the current evidence and future perspectives on the use of circulating tumour DNA (ctDNA) in the diagnosis, management and understanding the prognosis of patients with intrahepatic cholangiocarcinoma (iCCA) undergoing surgery. Liquid biopsies or ctDNA maybe utilized to: (1) determine the molecular profile of the tumour and therefore guide the selection of molecular targeted therapy in the neoadjuvant setting, (2) form a surveillance tool for the detection of minimal residual disease or cancer recurrence after surgery, and (3) diagnose and screen for early iCCA detection in high-risk populations. The potential for ctDNA can be tumour-informed or -uninformed depending on the goals of its use. Future studies will require ctDNA extraction technique validations, with standardizations of both the platforms and the timing of ctDNA collections
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Assaigs clĂnics; CĂ ncer de fetgeCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Ensayos clĂnicos; Cáncer de hĂgadoCoronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Clinical trials; Liver cancerBackground & aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.
Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave.
Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).
Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making.
Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.There was no funding for this study
Evaluating the predictive performance and transferability of machine learning-based prediction models using national liver transplant data registries
Patient Selection for Downstaging of Hepatocellular Carcinoma Prior to Liver Transplantation Adjusting the Odds?: Adjusting the Odds?
Background and Aims: Morphometric features such as the Milan criteria serve as
standard criteria for liver transplantation (LT) in patients with hepatocellular carcinoma
(HCC). Since it has been recognized that these criteria are too restrictive and do not
adequately display the tumor biology, additional selection parameters are emerging.
Methods: Concise review of the current literature on patient selection for downstaging and
LT for HCC outside the Milan criteria.
Results: The major task in patients outside the Milan criteria is the need for higher granularity
with patient selection, since the benefit through LT is not uniform. The recent literature clearly
shows that beneath tumor size and number, additional selection parameters are useful in the
process of patient selection for and during downstaging. For initial patient selection, the
alpha fetoprotein (AFP) level adds additional information to the size and number of HCC
nodules concerning the chance of successful downstaging and LT. This effect is quantifiable
using newer selection tools like the WE (West-Eastern) downstaging criteria or the
Metroticket 2.0 criteria. Also an initial PET-scan and/or tumor biopsy can be helpful,
especially in the high risk group of patients outside the University of California San
Francisco (UCSF) criteria. After this entry selection, the clinical course during
downstaging procedures concerning the tumor and the AFP response is of paramount
importance and serves as an additional final selection tool
Conclusion: Selection criteria for liver transplantation in HCC patients are becoming more
and more sophisticated, but are still imperfect. The implementation of molecular
knowledge will hopefully support a more specific risk prediction for HCC patients in
the future, but do not provide a profound basis for clinical decision-making at present
Evaluating the performance and external validity of machine learning-based prediction models in liver transplantation: an international study
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
Background & Aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare
systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC
screening or procedures has been interrupted or delayed because of the COVID-19 pandemic.
Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from
March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on
patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first
COVID-19 pandemic wave.
Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America,
North America, Asia, and Africa (73.7%,17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres
modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or
palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in
which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The
phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37).
Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver
cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of
patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies imple mented, aiding future decision-making
- …